Viewing Study NCT01465334

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:37 AM
Ignite Modification Date: 2026-07-15 @ 7:47 AM
Study NCT ID: NCT01465334
Status: TERMINATED
Last Update Posted: 2023-08-29
First Post: 2011-10-18
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
Sponsor: Dana-Farber Cancer Institute
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None CLL View
None SLL View
Keywords:

Keywords

Keyword Brief Keyword Text View
None 17p Deletion CLL View